These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 26752418)

  • 1. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
    Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
    PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
    Moyal L; Goldfeiz N; Gorovitz B; Rephaeli A; Tal E; Tarasenko N; Nudelman A; Ziv Y; Hodak E
    Invest New Drugs; 2018 Feb; 36(1):1-9. PubMed ID: 28884410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.
    Moyal L; Yehezkel S; Gorovitz B; Keren A; Gilhar A; Lubin I; Sherman S; Hodak E
    Br J Dermatol; 2017 Sep; 177(3):791-800. PubMed ID: 28256712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Richon V; Ni X; Talpur R; Duvic M
    J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells.
    Zhang C; Ni X; Konopleva M; Andreeff M; Duvic M
    J Invest Dermatol; 2004 Aug; 123(2):380-7. PubMed ID: 15245439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
    Heinicke U; Fulda S
    Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
    Zirlik K; Nashan D; Veelken H
    Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
    [No Abstract]   [Full Text] [Related]  

  • 10. Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach.
    Ragheb R; Venton G; Chelbi R; Bonnet N; Le Treut T; Ivanov V; Mercier C; Poulin P; Beaufils N; Gabert J; Suchon P; Rihet P; Loriod B; Kahn-Perlès B; Costello RT
    Arch Dermatol Res; 2017 Oct; 309(8):611-623. PubMed ID: 28695331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
    Trager MH; Geskin LJ
    G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.